InfliximabInfliximab (Remicade®) is a chimeric human/mouse monoclonal antibody that targets tumor necrosis factor alpha (TNFα).
Excess amounts of TNFα are associated with the development of immune diseases. Infliximab neutralizes the biological activity of TNF-α by inhibiting effective binding of TNF-α with its receptors. Extracellular, transmembrane, and receptor-bound forms of TNF-α are all neutralized by infliximab.
Neutralizing TNF-α activity results in dampening of the immune response. Treatment with infliximab has been described to decrease signs and symptoms of various auto-immune disease.
In Europe, infliximab is indicated for the treatment of:
- rheumatoid arthritis (in combination with methotrexate)
- psoriatic arthritis
- rheumatoid colitis
- ulcerative Crohn disease
- ankylosing spondylitis.
What can Sanquin do for you?
- Measure levels of free drug in the serum; levels of therapeutic antibodies are assessed using validated ELISAs.
- Measure the immunogenicity of adalimumab; human anti-human antibodies are quantified using validated antigen-binding tests (radioimmunoassay or RIA).